The research study is being conducted to determine the effectiveness of using hyperpolarized xenon-129 magnetic resonance imaging (MRI) in diagnosing and predicting treatment outcomes for patients who received endobronchial valve (EBV) therapy to treat chronic obstructive pulmonary disease (COPD). COPD is a disease of the lungs caused most often by smoking. Bronchoscopic lung volume reduction (BLVR), is an FDA approved treatment for select patients with severe COPD. PArticipants will be asked to complete the following research procedures: • Quality of Life Pulmonary Questionnaires: o St. Georges Respiratory Questionnaire o Modified Medical Research Council Questionnaire o COPD Assessment Test (CAT) • Pulmonary function test (if not completed with your physician prior to attending the study) • Practice for the breathing procedure being performed during the study • MRI scanning using the inhaled MRI contrast agent Hyperpolarized Xenon-129 (HP 129Xe) Participation will last for up to one year.

You may be eligible for this study if you meet the following criteria:

• Conditions: chronic obstructive pulmonary disease,COPD
• Age: 18 years - 99 years
• Gender: All